Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation

Neurobiology of Aging

Volumn 25, Issue 9, 2004, Pages 1153-1167

  Nilsson, Lars N G ^a,b   Arendash, Gary W ^c   Leighty, Ralph E ^c   Costa, David A ^a   Low, Mark A ^c   Garcia, Marcos F ^c   Cracciolo, Jennifer R ^c   Rojiani, Amyn ^d   Wu, Xin ^e   Bales, Kelly R ^e   Paul, Steven M ^e   Potter, Huntington ^a,f  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c SCA112 Coll Arts Sci Univ S F   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Alzheimer's disease; Amyloid deposition; Amyloid peptide; Apolipoprotein E; Inflammation; Learning; Memory; Transgenic mice; 1 Antichymotrypsin

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E;

AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALYSIS; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; HIPPOCAMPUS; IMMUNOREACTIVITY; LEARNING DISORDER; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; RISK FACTOR;

EID: 4043104729     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2003.12.011     Document Type: Article

References (76)

1. Abraham C.R., Selkoe D.J., Potter H. Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell. 52:1988;487-501
2. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., et al. Inflammation and Alzheimer's disease. Neurobiol. Aging. 21:2000;383-421
3. Anderson R., Barnes J.C., Bliss T.V., Cain D.P., Cambon K., Davies H.A., et al. Behavioural, physiological and morphological analysis of a line of apolipoprotein E knockout mouse. Neuroscience. 85:1998;93-110
4. Anderson R., Higgins G.A. Absence of central cholinergic deficits in ApoE knockout mice. Psychopharmacology (Berl). 132:1997;135-144
5. Arendash G.W., Gordon M.N., Diamond D.M., Austin L.A., Hatcher J.M., Jantzen P., et al. Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory. DNA Cell Biol. 20:2001;737-744
6. Arendash G.W., King D.L., Gordon M.N., Morgan D., Hatcher J.M., Hope C.E., et al. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res. 891:2001;42-53
7. Bales K.R., Verina T., Cummins D.J., Du Y., Dodel R.C., Saura J., et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 96:1999;15233-15238
8. Bales K.R., Verina T., Dodel R.C., Du Y., Altstiel L., Bender M., et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 17:1997;263-264
9. Buttini M., Yu G.Q., Shockley K., Huang Y., Jones B., Masliah E., et al. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J. Neurosci. 22:2002;10539-10548
10. Buxbaum J.D., Oishi M., Chen H.I., Pinkas-Kramarski R., Jaffe E.A., Gandy S.E., et al. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc. Natl. Acad. Sci. USA. 89:1992;10075-10078
11. Champagne D., Dupuy J.B., Rochford J., Poirier J. Apolipoprotein E knockout mice display procedural deficits in the Morris Water Maze: analysis of learning strategies in three versions of the task. Neuroscience. 114:2002;641-654
12. Chen G., Chen K.S., Knox J., Inglis J., Bernard A., Martin S.J., et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature. 408:2000;975-979
13. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261:1993;921-923
14. Das S., Potter H. Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1. Neuron. 14:1995;447-456
15. DeKosky S.T., Ikonomovic M.D., Wang X., Farlow M., Wisniewski S., Lopez O.L., et al. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment. Ann. Neurol. 53:2003;81-90
16. DeMattos R.B., O'Dell M.A., Parsadanian M., Taylor J.W., Harmony J.A., Bales K.R., et al. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 99:2002;10843-10848
17. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 5:2002;452-457
18. Dodart J.C., Bales K.R., Johnstone E.M., Little S.P., Paul S.M. Apolipoprotein E alters the processing of the beta-amyloid precursor protein in APP(V717F) transgenic mice. Brain Res. 955:2002;191-199
19. Dodart J.C., Mathis C., Bales K.R., Paul S.M., Ungerer A. Behavioral deficits in APP(V717F) transgenic mice deficient for the apolipoprotein E gene. Neuroreport. 11:2000;603-607
20. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-tur J., et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 383:1996;710-713
21. Fagan A.M., Watson M., Parsadanian M., Bales K.R., Paul S.M., Holtzman D.M. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 9:2002;305-318
22. Forloni G., Demicheli F., Giorgi S., Bendotti C., Angeretti N. Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by interleukin-1. Brain Res. Mol. Brain Res. 16:1992;128-134
23. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 373:1995;523-527
24. Goldgaber D., Harris H.W., Hla T., Maciag T., Donnelly R.J., Jacobsen J.S., et al. Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc. Natl. Acad. Sci. USA. 86:1989;7606-7610
25. Gordon M.N., King D.L., Diamond D.M., Jantzen P.T., Boyett K.V., Hope C.E., et al. Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol. Aging. 22:2001;377-385
26. Hardy J. Pathways to primary neurodegenerative disease. Ann. NY Acad. Sci. 924:2000;29-34
27. Harper J.D., Wong S.S., Lieber C.M., Lansbury P.T. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem. Biol. 4:1997;119-125
28. Holtzman D.M., Bales K.R., Tenkova T., Fagan A.M., Parsadanian M., Sartorius L.J., et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 97:2000;2892-2897
29. Janciauskiene S., Rubin H., Lukacs C.M., Wright H.T. Alzheimer's peptide Abeta1-42 binds to two beta-sheets of alpha1-antichymotrypsin and transforms it from inhibitor to substrate. J. Biol. Chem. 273:1998;28360-28364
30. *4-associated Alzheimer's disease risk is modified by alpha 1-antichymotrypsin polymorphism. Nat. Genet. 10:1995;486-488
31. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA. 95:1998;6448-6453
32. Licastro F., Mallory M., Hansen L.A., Masliah E. Increased levels of alpha-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype. J. Neuroimmunol. 88:1998;105-110
33. Lim G.P., Yang F., Chu T., Chen P., Beech W., Teter B., et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20:2000;5709-5714
34. Lukacs C.M., Christianson D.W. Is the binding of beta-amyloid protein to antichymotrypsin in Alzheimer plaques mediated by a beta-strand insertion? Proteins. 25:1996;420-424
35. Ma J., Brewer H.B. Jr., Potter H. Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4 inhibition by A beta-related peptides. Neurobiol. Aging. 17:1996;773-780
36. Ma J., Yee A., Brewer H.B. Jr., Das S., Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 372:1994;92-94
37. McGeer P.L., McGeer E., Rogers J., Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet. 335:1990;1037
38. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:2000;982-985
39. Morris R.G., Garrud P., Rawlins J.N., O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature. 297:1982;681-683
40. Mrak R.E., Griffin W.S. Interleukin-1 and the immunogenetics of Alzheimer disease. J. Neuropathol. Exp. Neurol. 59:2000;471-476
41. Mucke L., Yu G.Q., McConlogue L., Rockenstein E.M., Abraham C.R., Masliah E. Astroglial expression of human alpha(1)-antichymotrypsin enhances alzheimer-like pathology in amyloid protein precursor transgenic mice. Am. J. Pathol. 157:2000;2003-2010
42. Mueggler T., Sturchler-Pierrat C., Baumann D., Rausch M., Staufenbiel M., Rudin M. Compromised hemodynamic response in amyloid precursor protein transgenic mice. J. Neurosci. 22:2002;7218-7224
43. Namba Y., Tomonaga M., Kawasaki H., Otomo E., Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541:1991;163-166
44. Nilsson L., Rogers J., Potter H. The essential role of inflammation and induced gene expression in the pathogenic pathway of Alzheimer's disease. Front Biosci. 3:1998;d436-d446
45. Nilsson L.N., Bales K.R., DiCarlo G., Gordon M.N., Morgan D., Paul S.M., et al. Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 21:2001;1444-1451
46. Nilsson L.N., Das S., Potter H. Effect of cytokines, dexamethasone and the A/T-signal peptide polymorphism on the expression of alpha(1)- antichymotrypsin in astrocytes: significance for Alzheimer's disease. Neurochem. Int. 39:2001;361-370
47. Oda T., Wals P., Osterburg H.H., Johnson S.A., Pasinetti G.M., Morgan T.E., et al. Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp. Neurol. 136:1995;22-31
48. Owen E.H., Logue S.F., Rasmussen D.L., Wehner J.M. Assessment of learning by the Morris water task and fear conditioning in inbred mouse strains and F1 hybrids: implications of genetic background for single gene mutations and quantitative trait loci analyses. Neuroscience. 80:1997;1087-1099
49. Poirier J. Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Ann. NY Acad. Sci. 924:2000;81-90
50. Potter H, Abraham CR, Dressler D. The two Alzheimers amyloid components a-antichymotrypsin and b-protein form a stable complex in vitro. In: Iqbal K, McLachlan D, Winblad B, Wisniewski H, editors. Alzheimer's disease basic mechanisms, diagnosis and therapuetic strategies. New York: John Wiley and Sons Ltd.; 1991.
51. Potter H., Wefes I.M., Nilsson L.N. The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation. Neurobiol. Aging. 22:2001;923-930
52. Price D.L., Sisodia S.S. Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci. 21:1998;479-505
53. Qiao X., Cummins D.J., Paul S.M. Neuroinflammation-induced acceleration of amyloid deposition in the APPV717F transgenic mouse. Eur. J. Neurosci. 14:2001;474-482
54. Rogers D.C., Jones D.N., Nelson P.R., Jones C.M., Quilter C.A., Robinson T.L., et al. Use of SHIRPA and discriminant analysis to characterise marked differences in the behavioural phenotype of six inbred mouse strains. Behav. Brain Res. 105:1999;207-217
55. Rogers J.T., Leiter L.M., McPhee J., Cahill C.M., Zhan S.S., Potter H., et al. Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5'-untranslated region sequences. J. Biol. Chem. 274:1999;6421-6431
56. Sanan D.A., Weisgraber K.H., Russell S.J., Mahley R.W., Huang D., Saunders A., et al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J. Clin. Invest. 94:1994;860-869
57. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2:1996;864-870
58. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:2001;741-766
59. Strittmatter W.J., Roses A.D. Apolipoprotein E and Alzheimer disease. Proc. Natl. Acad. Sci. USA. 92:1995;4725-4727
60. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90:1993;1977-1981
61. Telling G.C., Scott M., Mastrianni J., Gabizon R., Torchia M., Cohen F.E., et al. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell. 83:1995;79-90
62. Terai K., Iwai A., Kawabata S., Sasamata M., Miyata K., Yamaguchi T. Apolipoprotein E deposition and astrogliosis are associated with maturation of beta-amyloid plaques in betaAPPswe transgenic mouse: implications for the pathogenesis of Alzheimer's disease. Brain Res. 900:2001;48-56
63. Thomas T., Thomas G., McLendon C., Sutton T., Mullan M. Beta-amyloid-mediated vasoactivity and vascular endothelial damage. Nature. 380:1996;168-171
64. Veinbergs I., Masliah E. Synaptic alterations in apolipoprotein E knockout mice. Neuroscience. 91:1999;401-403
65. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 416:2002;535-539
66. Walsh D.M., Lomakin A., Benedek G.B., Condron M.M., Teplow D.B. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 272:1997;22364-22372
67. Walsh D.M., Tseng B.P., Rydel R.E., Podlisny M.B., Selkoe D.J. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry. 39:2000;10831-10839
68. Wang H.W., Pasternak J.F., Kuo H., Ristic H., Lambert M.P., Chromy B., et al. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924:2002;133-140
69. Webster S., Rogers J. Relative efficacies of amyloid beta peptide (A beta) binding proteins in A beta aggregation. J. Neurosci. Res. 46:1996;58-66
70. Wei A., Rubin H., Cooperman B.S., Schechter N., Christianson D.W. Crystallization, activity assay and preliminary X-ray diffraction analysis of the uncleaved form of the serpin antichymotrypsin. J. Mol. Biol. 226:1992;273-276
71. Wisniewski T., Aucouturier P., Soto C., Frangione B. The prionoses and other conformational disorders. Amyloid. 5:1998;212-224
72. Wisniewski T., Castano E.M., Golabek A., Vogel T., Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am. J. Pathol. 145:1994;1030-1035
73. Wisniewski T., Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett. 135:1992;235-238
74. Xu P.T., Gilbert J.R., Qiu H.L., Ervin J., Rothrock-Christian T.R., Hulette C., et al. Specific regional transcription of apolipoprotein E in human brain neurons. Am. J. Pathol. 154:1999;601-611
75. Yamada M., Sodeyama N., Itoh Y., Suematsu N., Otomo E., Matsushita M., et al. Association of alpha1-antichymotrypsin polymorphism with cerebral amyloid angiopathy. Ann. Neurol. 44:1998;129-131
76. Yamin R., Malgeri E.G., Sloane J.A., McGraw W.T., Abraham C.R. Metalloendopeptidase EC 3.4.24.15 is necessary for Alzheimer's amyloid-beta peptide degradation. J. Biol. Chem. 274:1999;18777-18784